Hospital Universitario de Donostia-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

2021

  1. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  2. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage

    Nature Communications, Vol. 12, Núm. 1

2019

  1. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease

    Movement Disorders, Vol. 34, Núm. 9, pp. 1333-1344

  2. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

2017

  1. A protective personal factor against disability and dependence in the elderly: an ordinal regression analysis with nine geographically-defined samples from Spain

    BMC Geriatrics, Vol. 17, Núm. 1, pp. 1-10

2016

  1. Dysexecutive syndrome in amnesic mild cognitive impairment: A multicenter study

    BMC Neurology, Vol. 16, Núm. 1

2015

  1. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations

    Parkinsonism and Related Disorders, Vol. 21, Núm. 7, pp. 717-722

2013

  1. Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE ε4 carriers: A case-control study

    BMJ Open, Vol. 3, Núm. 9